Canine Melanoma Vaccine Gets Conditional OKMay 23, 2007 The U.S. Department of Agriculture has conditionally licensed a vaccine to treat canine oral melanoma—the first approved therapeutic vaccine for the treatment of cancer in either animals or humans, according to the company that produces it, Merial. The vaccine is indicated for the treatment of dogs with stage II or stage III oral melanoma for which local disease control has been achieved. It has been in the making for some time. Merial has been involved with the research for four to five years, said Bob Nordgren, Ph.D., vice president of biologics research, development and technology acquisition for Merial. The initial research, however, began even further back. Ongoing research into human treatments that was being conducted by Jedd Wolchok, MD, Ph.D., at Memorial Sloan-Kettering Cancer Center in New York City led to collaboration with Philip Bergman, DVM, Ph.D., Dipl. ACVIM (Oncology) at the Animal Medical Center in New York. The collaboration resulted in the canine melanoma vaccine. Dr. Bergman approached Merial to support the research, which helped further develop and refine the vaccine. The vaccine alerts the immune system to the presence of the melanoma tumor protein tyrosinase. The vaccine uses a gene for …
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
The Pain PrognosisMay 23, 2007Every day, it seems, research sheds more light on the physiological avenues of pain, revealing new opportunities to improve quality of life. The trick, of course, is to translate those insights into tools of measurement and treatment that make a real-world difference for animals in pain. To gain a better understanding of the near- and long-term future of pain management, we asked seven veterinary experts from the pharmaceutical industry, academic research and clinical practice to give their prognoses. On more than a few fronts, they see reasons for optimism. In their eyes, hope takes the form of: New pain scales that remove much of the guesswork from assessment. NSAIDs and opioids that better target specific diseases and other ailments. Research that yields novel uses for existing medications. Sustained-release drugs that take compliance off the list of concerns. With some of these and other predictions, it’s hard to separate aspiration from expectation, while in other areas, forecasts are already coming true. For instance, existing drugs are regularly being used to treat pain in new ways. On two points, at least, the experts agree: This is an exciting, dynamic time to tackle issues of pain management and prevention. A world of progress …
How To Treat The Rare And Deadly Nasal Cancer In Dogs And CatsNovember 1, 2004Nasal passage cancer generally develops very insidiously in older pets. It is rare in cats and not common in dogs. It composes about 1 percent of feline tumors and up to 2.5 percent of canine tumors. Long-nosed breeds (dolichocephalic) and senior dogs are at higher risk. Clinical Signs Of Nasal Passage The early signs of nasal cancer in dogs or cats are: Unilateral nasal and/or ocular discharge Epistaxis Stridor Loss of smell Loose teeth Sometimes pawing at the face Late-stage signs may include a facial deformity along the dorsal aspect of the maxillary bones or over the paranasal and frontal sinuses. Some cases develop a raised or pitting facial bone deformity. Some cases may exhibit a firm or soft focal, raised mass protruding around or between the eyes. Some cases may have a palatine deformity from the softening and bowing out of the hard palate due to demineralization of the palatine bone and growth of the mass. In every case of facial deformity, there is bone lysis and tumor invasion at that site. If the lesions extend into the brain, seizures and behavior changes are often exhibited. A complication of nasal cancer is the over production of mucus. It …
